Supernus Adds To CNS Portfolio, Especially In Parkinson’s, With Adamas Buyout

 
• By Joseph Haas
  
Mergers
Supernus adds to its CNS portfolio with $400m buyout of Adamas
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business